Table 1.
Patient Characteristics
| Patient Characteristics | |
|---|---|
|
Total, n Evaluable anti-SARS-Cov-2 antibodies |
104 17 |
|
Gender, male, n (%) |
75 (72) 13 (76) |
| Age, median (range) | 59.0 (19-79) 64 (35-77) |
|
Race/ethnicity White, n, (%) Hispanic or Latino, n (%) African American, n (%) Asian, n (%) Pacific Islander, n (%) American Indian, n (%) Other, n (%) Missing, n (%) |
86 (83) 13 (76) 8 (7.7) 4 (3.8) 1 (1.0) 1 (1.0) 1 (1.0) 2 (1.9) 1 (1.0) |
| BMI, median (range) | 26 (17.9-53.8) 28 (18.3 -34.7) |
|
Diagnosis NHL, n (%) MM, n (%) |
76 (73) 10 (59) 26 (25.0) 7 (41) |
|
Survival status Alive, n (%) Deceased, n (%) |
73 (70.) 31 (30) |
| COVID-19 pre-CAR T, n (%) | 7 (7) 2 (12) |
| Days from COVID-19 to CAR T, median (range) | 220 (30-265) (112-161) |
|
ASCT pre-CAR T NHL, n (%) MM, n (%) |
18 (17) 4 (40) 20 (19) 6 (86) |
| Days ASCT to CAR T median (range) | 605 (138-4409) 881 (272-2502) |
| Vaccinated pre-CAR T, n (%) | 4 (4) 3 (18) |
| COVID-19 post-CAR T, n (%) | 19 (18) $2 |
| Days from CAR T to COVID-19, median (range) | 220 (7-1406) |
| Days from CAR T to vaccine, median (range) | 170 (32-881) 95 (28-792) |
| Antibody info for vaccinated, n (%) | 17 (16) |
| % positive for antibody that had a vaccine, n (%) | 13 (76) |
| % negative for antibody that had a vaccine, n (%) | 4 (24) |
|
Cell and IgG Count WBC, median (range) ALC, median (range) CD4, median (range) IgG, median (range) |
3.6 × 104/µL (0.2-28.2) 5 × 104/µL (1.3-28.2) 0.64 × 104/µL (0.03-870) 0.73 × 104/µL (0.28-3.43) 110 × 106/µL (4-829) 137 × 104/µL (34-543) 517 g/L (<300-3611) 553 g/L (<300-3611) |
| Received IVIG post-CAR T, n (%) | 46 (44) 7 (41) |
|
Disease status post-CAR T Remission, n (%) Progression, n (%) Missing, n (%) |
58 (56) 11 (65) 43 (41) 5 (29) 3 (3) 1 |
| Received Rx post-CAR T, n (%) | 41 (39) 4 (24%) |
Characteristics of the 17 patients with evaluable anti-SARS-Cov-2 antibodies are represented in blue font. Survival status is based on the month/year of September 2021 for the cohort as a whole. Specific survival status for the 17 patients with evaluable anti-SARS-Cov-2 antibodies is discussed in the text as survival follow up was completed at a later date.
Abbreviations: ALC = absolute reticulocyte count; BMI = body mass index; CAR T: chimeric antigen receptor T-cells; IgG = immunoglobulin G; MM = multiple myeloma; N = number of patients; NHL = non-Hodgkin lymphoma; Rx = treatment; WBC = white blood cell count.